I'm LongbridgeAI, I can summarize articles.Hong Kong's consumer sector is undergoing strategic consolidation as key players align with policy shifts. China Resources Pharmaceutical (3320.HK) reported Q2 revenue of CNY 659.33 billion, with distribution accounting for 78.09% following its June 2026 partnership with Sinopharm Group to expand digital supply chains. The acquisition of 51% stake in Sanjiu Pharmaceutical for CNY 1.79 billion further streamlined its manufacturing vertical. iDreamSky (1119.HK) granted 8.28 million stock options to core staff at HKD 3.01 per share, while retiring 4.58 million repurchased shares to optimize capital structure. Yixin Group (1833.HK) captured momentum from Shanghai's auto stimulus policies, generating CNY 12.51 billion in Q2 revenue through integrated financing platforms that now resonate with broader consumption recovery trends. These moves collectively signal a pivot toward ecosystem-driven growth models amid sector-wide recalibration.
